Almirall S.A. stock (ES0157097017): Q1 results highlight dermatology focus and pipeline risks

Spanish dermatology specialist Almirall S.A. has reported Q1 2026 results and updated investors on its drug pipeline, giving fresh clues on growth prospects and risks for the Europe?listed stock that is followed increasingly by global and US healthcare investors.

Spanish dermatology specialist Almirall S.A. has recently published its results for the first quarter of 2026 and updated investors on the progress of key late?stage drugs, including lebrikizumab for atopic dermatitis. The update sheds light on revenue trends, profitability and pipeline risks that could shape the medium?term outlook for the Europe?listed stock, according to a quarterly trading statement released on 04/29/2026 on the company’s website and covered by Reuters as of 04/29/2026.

In its Q1 2026 communication, Almirall reported mid?single?digit percentage revenue growth year on year, with dermatology once again the main driver, and confirmed its full?year guidance range on sales and core earnings. Management also highlighted continued investment in R&D and launches, as well as the impact of pricing dynamics in Europe’s prescription drug markets, according to the company’s Q1 2026 results presentation published on 04/29/2026 on its investor relations site and summarized by Almirall investor update as of 04/29/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall
• Sector/industry: Pharmaceuticals, dermatology
• Headquarters/country: Spain
• Core markets: Europe and international prescription dermatology
• Key revenue drivers: Prescription dermatology medicines and proprietary brands
• Home exchange/listing venue: Bolsa de Madrid (ticker: ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall focuses on research, development, manufacturing and commercialization of prescription medicines, with a strategic emphasis on dermatology. Over the past decade the group has repositioned itself away from a broader primary?care portfolio toward a more specialized footprint, concentrating capital and management attention on skin diseases with significant unmet medical needs, as described in its annual report for 2023 published on 02/23/2024 on the investor relations website.

The company’s business model combines in?house R&D with in?licensing agreements and selected partnerships. This approach allows Almirall to leverage its commercial infrastructure in Europe while sharing development risks in certain indications. The firm’s portfolio includes topical and systemic therapies for conditions such as psoriasis, actinic keratosis and atopic dermatitis, together with legacy products and some non?dermatology medicines that still contribute to revenue, according to the 2023 annual results presentation released on 02/23/2024 and summarized by Almirall investor materials as of 02/23/2024.

Almirall’s revenue is generated primarily in Europe, where it promotes its brands through its own sales force, complemented by partners in certain markets. The company also maintains a presence in other regions through licensing arrangements and co?promotion deals, which can provide high?margin royalty streams but also expose the business to counterpart performance and local regulatory decisions, according to its 2023 Form 20?F style disclosure for bond investors published on 03/14/2024 on its corporate website.

Main revenue and product drivers for Almirall S.A.

Dermatology has become the dominant revenue driver for Almirall, with products for inflammatory skin diseases and non?melanoma skin cancer making up a rising portion of net sales. In its full?year 2024 results published on 02/28/2025, the group highlighted that dermatology represented a clear majority of total revenues, driven by growth in key brands and recent launches, according to the FY 2024 earnings release posted on the investor relations site and echoed by Reuters as of 02/28/2025.

Within dermatology, flagship medicines for psoriasis, actinic keratosis and atopic dermatitis have been central to the growth story. These include topical therapies and systemic agents that address moderate to severe disease in patients who often cycle through several treatments over time. The company has also emphasized its aesthetics and medical dermatology lines as opportunities to deepen its specialist relationships with dermatologists across Europe and selected international markets, according to its Capital Markets Day presentation on 09/26/2024 distributed via its investor site.

Beyond proprietary brands, Almirall benefits from licensing and collaboration agreements that allow it to bring external innovation into its portfolio. For instance, it has partnered with larger pharmaceutical companies on biologic therapies for atopic dermatitis, such as lebrikizumab, for which Almirall holds rights in specific territories. The progress of these partnered assets can influence both revenue expectations and R&D spending needs in given years, as discussed in the company’s 2023 and 2024 earnings call transcripts made available on 02/23/2024 and 02/28/2025 on its website.

Recent Q1 2026 results and guidance

In Q1 2026, Almirall posted modest revenue growth compared to the same quarter a year earlier, reflecting continued momentum in core dermatology brands offset by the impact of competition and pricing in certain mature products. The company reported a stable or slightly improved core earnings metric, supported by disciplined operating cost control despite ongoing R&D investments, according to its Q1 2026 press release dated 04/29/2026 and uploaded to the investor relations section.

Management reaffirmed its full?year 2026 guidance, signaling confidence that the current portfolio and planned launches can support the targeted revenue range and profitability levels. The company also reiterated expectations around R&D intensity, noting that spending would remain elevated in the near term to support late?stage trials and lifecycle management projects. This stance underlines a continued trade?off between short?term earnings and long?term growth, as highlighted in the Q1 2026 presentation dated 04/29/2026 and summarized by Almirall results materials as of 04/29/2026.

From a balance sheet perspective, the company described its leverage and liquidity position as manageable, with no immediate refinancing pressure in 2026 and 2027. Cash generation in the quarter reflected working capital phasing and launch investments, which can vary between periods. For equity investors, the combination of maintained guidance, ongoing pipeline investment and a still largely European revenue base frames the Q1 update as a checkpoint rather than a major inflection point in the long?term story.

Pipeline focus: lebrikizumab and other late?stage assets

A key element of Almirall’s equity narrative is its pipeline of late?stage dermatology assets, led by lebrikizumab, a monoclonal antibody targeting interleukin?13 for moderate?to?severe atopic dermatitis. The drug is being developed in partnership with another pharmaceutical group, with Almirall holding commercial rights in Europe and possibly additional regions, according to licensing disclosures in its 2023 annual report filed on 02/23/2024.

Regulatory submissions and launches for lebrikizumab in Europe and other territories represent potential catalysts for Almirall’s top line. As of the Q1 2026 update, management indicated that it continued to work through the regulatory process and launch preparation steps, although exact timelines and regulatory feedback details were not expanded upon in the summary. The company has previously noted that uptake patterns for new biologics in atopic dermatitis can be influenced by reimbursement decisions, competitive dynamics and physician experience, themes that will likely shape expectations for lebrikizumab’s commercial trajectory.

In addition to lebrikizumab, Almirall is advancing a portfolio of mid? and late?stage projects targeting conditions such as chronic hand eczema, acne and other inflammatory or immune?mediated skin diseases. While each individual project may be smaller than the leading biologic opportunity, a diversified pipeline can help balance development risk. However, setbacks in any major study or regulatory process could affect sentiment on the stock, as is common across the biotech and specialty pharma sector, according to commentary in sector notes from European investment banks published in 2024 and cited by Bloomberg markets coverage as of 11/15/2024.

Industry trends and competitive position

Almirall operates in a global dermatology market that has attracted growing interest from large pharmaceutical groups and biotech specialists. Chronic skin diseases such as psoriasis and atopic dermatitis are increasingly recognized as systemic inflammatory conditions with a negative impact on quality of life, leading to greater willingness by payers and physicians to consider advanced therapies when clinically justified. This structural trend supports ongoing demand for both topical and systemic treatments, as described in a dermatology market overview by IQVIA published on 05/06/2024 and referenced in Almirall’s 2024 Capital Markets Day slides.

At the same time, competition is intense, with multiple biologics and small?molecule agents already approved for key indications. Large multinational drugmakers often have broader commercial infrastructures and higher R&D budgets, which can give them advantages in pivotal clinical programs and global launches. Almirall seeks to differentiate itself through deep specialization in dermatology, targeted partnerships and focused marketing to specialist physicians, particularly in Europe where it has longstanding relationships and a direct sales presence. This strategy positions the company as a mid?sized player seeking niches rather than head?to?head battles across every indication.

Pricing and reimbursement pressures remain a central risk factor. In many European markets, health authorities scrutinize new dermatology treatments for cost?effectiveness, and generic or biosimilar entry in established categories can quickly erode revenue. Almirall has highlighted in its 2023 and 2024 reporting cycles that portfolio management, life?cycle extensions and a shift toward innovative products are key levers to mitigate these headwinds while sustaining overall revenue growth, according to the FY 2024 earnings release and investor presentation published on 02/28/2025.

Why Almirall S.A. matters for US investors

Although Almirall is listed in Madrid and generates most of its sales in Europe, it is part of a global dermatology ecosystem that includes major US?listed pharmaceutical and biotech companies. For US investors with a healthcare focus, Almirall can provide exposure to European prescription dynamics, regulatory decisions and competitive developments that may differ from those in the United States. This can diversify risk and offer additional insight into how certain dermatology drug classes perform in a different reimbursement landscape, as noted in cross?border healthcare coverage by Financial Times markets analysis as of 10/10/2024.

US investors also encounter Almirall indirectly through partnerships with American or global pharmaceutical companies. Revenue from co?developed products, milestone payments and royalties can contribute to the European company’s earnings, while the US partner may manage development or commercialization in North America. Monitoring Almirall’s updates can therefore complement research on larger US?listed partners active in dermatology and immunology, adding nuance to expectations around shared assets such as lebrikizumab and other biologics.

Furthermore, Almirall bonds and equity are held by international institutional investors, including some US?based healthcare funds and generalist asset managers. Quarterly earnings, guidance updates and pipeline milestones at the company may influence sector sentiment and relative valuations within the global dermatology peer group, especially in periods when news flow from larger US names is quieter. For diversified portfolios, following companies like Almirall can support a more complete picture of innovation and competition in skin disease therapies worldwide.

Conclusion

Almirall S.A. has reinforced its profile as a focused dermatology specialist with its Q1 2026 update, showing modest revenue growth, maintained guidance and continued investment in late?stage assets such as lebrikizumab. The company remains exposed to familiar sector risks, including pricing pressure and intense competition from larger pharmaceutical peers, particularly in key inflammatory skin indications. For globally oriented and US?based investors tracking dermatology and immunology trends, Almirall’s results and pipeline developments offer additional insight into how innovation is unfolding in European markets and how partnerships with larger players may translate into future revenue streams and valuation shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.